{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.9","value":"2670"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5","value":"4930"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"AUCinf is the AUC from time zero to infinity (mass x time x volume-1).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received sabatolimab","id":"OG000","title":"Sabatolimab (MBG453)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set (PAS) included all participants in the Safety Set, who had at least one evaluable PK concentration.\n\nSafety Set included all participants who received at least one dose of any component of the study treatment, and they were analyzed according to the study treatment they received.","reportingStatus":"POSTED","timeFrame":"0 hr (pre-dose) & 2 hrs (post-dose) of Cycle (C) 1 Day (D) 8 and 0 hr (pre-dose) & 2 hrs (post-dose) of C3D8","title":"Pharmacokinetics of MBG453 (Parameter AUC)","type":"SECONDARY","unitOfMeasure":"day*ug/ml"}